Showing 7691-7700 of 8649 results for "".
- iSTAR Medical’s Glaucoma Device MINIject Shows Positive One-Year Results in European Trialhttps://modernod.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/iSTAR Medical announced positive 1-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held November 13-15 2020. Po
- Stoke Therapeutics Nominates Next Preclinical Target in Genetic Eye Diseasehttps://modernod.com/news/stoke-therapeutics-nominates-next-preclinical-target-in-genetic-eye-disease/2478539/Stoke Therapeutics announced the nomination of OPA1 as its second preclinical candidate. “Based on new preclinical data, we are announcing today the expansion of our pipeline with the nomination of OPA1 as our next preclinical target,” Edward M. Kaye, MD, Chief Executive Offi
- CDC Now Says Wearing a Mask Protects the Wearer, Toohttps://modernod.com/news/cdc-now-says-wearing-a-mask-protects-the-wearer-too/2478538/For months it has been clear that wearing a face mask reduces the transmission of COVID-19, because it prevents your respiratory droplets from spreading and potentially infecting other people. Now the Centers for Disease Control has highlighted another benefit of mask-wearing that many hoped or s
- EU Seals Deal For Up to 300 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/eu-seals-deal-for-up-to-300-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478528/The European Commission on Wednesday said it has finalized an advance purchase agreement with Pfizer and BioNTech for the initial supply of 200 million doses of their experimental COVID-19 vaccine, with an option to request up to a 100 million more. The announcement comes days after the companies
- Topology Introduces Proprietary Touchless Optical Platform (TOP)https://modernod.com/news/topology-introduces-proprietary-touchless-optical-platform-top/2478518/Topology announced the introduction of their proprietary Touchless Optical Platform (TOP), a technology platform aimed at improving the optical experience for patients and staff, while driving incremental revenue. With the Touchless Optical Platform, Eyewear sales are generated seamlessly,
- Hoya Surgical Optics Introduces On-Demand Platform Qube Pro Powered by Eyeflexahttps://modernod.com/news/hoya-surgical-optics-introduces-on-demand-platform-qube-pro-powered-by-eyeflexa/2478514/Hoya Surgical Optics obtained CE Mark for “Qube pro powered by eyeflexa,” a technology that can support both cataract and vitreoretinal surgery. Eyeflexa is a multi-upgrade platform designed to evolve with the changing needs of ophthalmic surgeons, according to a company news r
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p
- FDA Fast-Tracks Novavax COVID-19 Vaccine NVXCoV2373https://modernod.com/news/fda-fast-tracks-novavax-covid-19-vaccine-nvxcov2373/2478517/Novavax said Monday that its experimental COVID-19 vaccine NVX-CoV2373 has received fast-track designation from the FDA. The company also reiterated that it expects to begin a pivotal phase 3 trial of the candidate in the US and Mexico by the end of November, data from which could be used to supp
- Early Phase 3 Data Show Pfizer, BioNTech’s COVID-19 Vaccine Over 90% Effectivehttps://modernod.com/news/early-phase-3-data-show-pfizer-biontechs-covid-19-vaccine-over-90-effective/2478507/Results from the first interim analysis of a phase 3 study of Pfizer and BioNTech’s BNT162b2 showed that the experimental mRNA-based vaccine candidate was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced M
- Oxurion NV Confirms New Patents for THR-687 Issued by European and US Patent Officeshttps://modernod.com/news/oxurion-nv-confirms-new-patents-for-thr-687-issued-by-european-and-us-patent-offices/2478504/Oxurion NV announced a strengthening of its intellectual property (IP) portfolio governing THR-687, an integrin antagonist being developed for the treatment of DME. The European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) have both issued new composition-o